US FDA warns about PAH linked to BMS' leukaemia drug Sprycel
This article was originally published in Scrip
Executive Summary
The US FDA issued a new safety alert about the risk of pulmonary arterial hypertension (PAH) linked to Bristol-Myers Squibb's Sprycel (dasatinib), which is approved to treat certain adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia and acute lymphoblastic leukaemia.